GlassScriptPhysician profile
Robert Edward Cantu
NPI 1891771499
$5,674.47
in general payments reported to CMS, 2019-2025
24 companies · $831 in 2025
The $831 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $583 · 2021: $975 · 2022: $492 · 2023: $1,242 · 2024: $876 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,901 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,901.21 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $951.26 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $671.14 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $648.39 | 2022-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $618.40 | 2019-2024 | |
| Eisai INC. | $597.81 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $428.27 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $332.28 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $254.64 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $168.74 | 2020-2021 | |
| Lundbeck LLC | $143.65 | 2019-2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $137.94 | 2023-2024 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $132.65 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $94.00 | 2025 | Zepbound |
| Jazz Pharmaceuticals INC. | $84.42 | 2020-2021 | |
| Bausch Health US, LLC | $70.93 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $64.97 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $63.46 | 2019-2020 | |
| Allergan, INC. | $56.55 | 2019-2020 | |
| Shire North American Group INC | $36.36 | 2019 | |
| Corium, LLC | $33.62 | 2022 | |
| Neurocrine Biosciences, INC. | $31.50 | 2019 | |
| Vertical Pharmaceuticals, LLC | $19.10 | 2019 | |
| Adlon Therapeutics L.P. | $18.22 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.17 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cantu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.